|
|
| |
|
|
Symposium on Recent Advancements on Drug Discovery Science and Technology |
|
| |
|
Symposium on Novel Drug Delivery Systems and Technology |
|
| |
|
Symposium on New Discoveries and Achievements of Cancer Research |
|
| |
|
Symposium on Latest Advances in Cardiovascular Research and Therapeutics Development |
|
| |
|
Symposium on Innovation on CNS Research and Therapeutics Development |
|
| |
|
Symposium on Updates on Diabetes Research and Therapy |
|
|
| |
|
|
• Online Registration is Open
October 1st, 2019 |
|
• Call for speakers!
September 1st, 2019 |
|
• Welcome to the website of WCDI-2021
August 15th, 2019 |
|
|
| |
|
|
• Abstract Submission Start Day
September 1st, 2019 |
|
• Earlybird Registration Start Day
October 1st, 2019 |
|
• Earlybird Registration Deadline
December 31st, 2019
|
|
• Abstract Submission Deadline
June 30th, 2022
|
|
• Acceptance Notification Deadline
July 20 th, 2022 |
|
|
|
|
|
|
 |
Symposium on
Recent Advancements on Drug Discovery Science and Technology |
|
| |
Introduction |
| Symposium on Recent Advancements on Drug Discovery Science and Technology provides a platform to promote international exchanges for drug discovery, and to accelerate the cooperation for new drug research and development in the global market. This Symposium feature talks on the cutting edge of the discipline that include new compounds, targets, drug design, synthesis methods and technologies that advance the science from leaders in the pharmaceutical, biotech and academic spaces. |
Topics |
Session 1-1: Drug Discovery Biology |
Session 1-2: Drug Discovery Chemistry |
Session 1-3: Breaking Technology in Drug Design |
Session 1-4: Novel Drug Target Discovery and Validation |
Session 1-5: Omics Technologies in Drug Discovery |
Session 1-6: Drug Screening Technology |
Session 1-7: Translational Medicine and Drug Discovery |
Session 1-8: Biomarkers in Drug Discovery & Development |
Session 1-9: Drug Discovery Pharmacology and Toxicology |
Session 1-10: Marine Drugs and Natural Products in Drug Discovery and Development |
Session 1-11: Novel Drug Targets for Personalized Precision Medicine |
Session 1-12: Small Molecule Drug Discovery |
Session 1-13: CNS Drug Discovery & Therapy |
Session 1-14: Cardiovascular Drug Discovery & Therapy |
Session 1-15: Anti-Cancer Drug Discovery and Therapy |
Session 1-16: Emerging Infectious Diseases Drug Discovery and Therapy |
Session 1-17: Antibody Drug Discovery and Development |
Session 1-18: Biosimilar Drug Product Development |
|
|
AGENDA
Day 0, August 11, 2021
Registration
Day 1, August 12, 2021
MORNING
Opening Ceremony
Welcome Remark by Honorary Chairs
Dr. Andreas Strasse, Fellow Of The Australian Academy of Science; NHMRC Senior Principal Research Fellow, Alan W Harris Personal Chair, Walter And Eliza Hall Institute of Medical Research, Australia
Dr. Chong-Su Cho, Fellow of Korean Academy of Science and Technology, Fellow of International Union of Societies for Biomaterials Science and Engineering; Research Professor, Research Institute for Agriculture and Life Sciences, Seoul National University, South Korea
|
|
|
Keynote Forum I for Drug Discovery
|
|
|
|
Call for Chair |
|
|
Speech Time |
Speaker's Profile |
|
|
09:15-9:45 |
Title: GPCRomics: an approach to identify novel GPCR targets
Dr. Paul A. Insel, Distinguished Professor of Pharmacology and Distinguished Professor of Medicine,
Co-Director, Medical Scientist (MD/PhD) Training Program, University of California, San Diego, USA |
|
|
09:45-10:15 |
Title: Inhibitors of Bruton’s tyrosine kinase (BTK) are transforming leukemia and lymphoma treatment
Dr. C. I. Edvard SMITH, Professor, Karolinska Institute, Sweden |
|
|
10:15-10:45 |
Title: Peptide Based Radiopahrmaceuticals for Cancer Diagnosis
Dr. Yueqing Gu, Professor, Biomedical Engineering; Dean, School of Engineering; Director, Molecular imaging
and Biomedical Engineering
China Pharmaceutical University, China |
|
|
10:45-11:00 |
Coffee Break |
|
|
11:00-11:30 |
Title: The Dawning of a New Era in Drug Discovery and Development
Dr. Richard Soll, Senior Vice President, Research Service Division, WuXi AppTec, USA |
|
|
11:30-12:00 |
Speech Opportunity Available |
|
|
Day 1, August 12, 2021
AFTERNOON
|
|
Session 1-1: Drug Discovery Biology
|
|
|
|
|
Dr. Jun-Kyu Suh, Inha-Hanlym Distinguished Professor, National Research Center for Sexual Medicine,
Dept. of Urology, Inha University School of Medicine, South Korea |
|
|
Co-Chair |
Dr. Appu Rathinavelu, Executive Director , Rumbaugh Goodwin Institute for Cancer Research,
Nova Southeastern University, USA |
|
|
Speech Time |
Speaker's Profile |
|
|
13:30-13:55 |
Speech Opportunity Available |
|
|
13:55-14:20 |
Title: The exploration of novel HIV-1 NNRTIs
Dr. Shuang-Xi Gu, Professor, Key Laboratory for Green Chemical Process of Ministry of Education,
School of Chemical Engineering and Pharmacy, Wuhan Institute of Technology, China |
|
|
14:20-14:45 |
Title: Development of angiogenic protein for future therapy of erectile dysfunction
Dr. Jun-Kyu Suh, Inha-Hanlym Distinguished Professor, National Research Center for Sexual Medicine,
Dept. of Urology, Inha University School of Medicine, South Korea |
|
|
14:45-15:10 |
Title: Water Mediates Raman effect and its Application as Alternative Medicine in Cell Biology
Insang Lee, CEO of Divine Lab Co Ltd., South Korea |
|
|
15:10-15:30 |
Coffee Break |
|
|
|
|
Session 1-2: Drug Discovery Chemistry
|
|
|
|
Dr. Tomasz Janecki, Professor, Director of the Institute of Organic Chemistry, Lodz University of Technology, Poland |
|
|
Co-Chair |
Dr. George Kokotos, Professor of Organic and Medicinal Chemistry, Department of Chemistry, National and
Kapodistrian University of Athens, Greece |
|
|
Speech Time |
Speaker's Profile |
|
|
13:30-13:55 |
Speech Opportunity Available |
|
|
13:55-14:20 |
Title: Sesquiterpene lactones and related compounds as promising anticancer agents
Dr. Tomasz Janecki, Professor, Director of the Institute of Organic Chemistry, Lodz University of Technology, Poland |
|
|
14:20-14:45 |
Title: In-silico methodology that outperforms lab methods in predicting human clinical ADME/PK
Dr. Urban Fagerholm, Associate Professor, CEO at PROSILICO, Huddinge, Sweden |
|
|
14:45-15:10 |
Title: Discovery of novel bioactive lipids
Dr. George Kokotos, Professor of Organic and Medicinal Chemistry, Department of Chemistry, National and
Kapodistrian University of Athens, Greece |
|
|
15:10-15:30 |
Coffee Break |
|
|
|
|
Session 1-3: Breaking Technology in Drug Design
|
|
|
|
Dr. Nikolai Petrovsky, Professor, Flinders University, Australia |
|
|
Co-Chair |
Dr. Don Van Dyke Raleigh, NC Business Development Consultant Ontario Ministry of Economic Development &
Trade, Canada |
|
|
Speech Time |
Speaker's Profile |
|
|
13:30-13:55 |
Title: Quantum kernel energy method: Drug–target interaction energies for drug design
Dr. Lou Massa, Professor, Hunter College, City University of New York, USA |
|
|
13:55-14:20 |
Title: Lead Molecule Design Using AI
Dr. Don Van Dyke Raleigh, NC Business Development Consultant, Ontario Ministry of Economic Development
& Trade, Canada |
|
|
14:20-14:45 |
Speech Opportunity Available |
|
|
14:45-15:10 |
Title: High throughput methods for immuno-therapeutic drug design
Dr. Nikolai Petrovsky, Professor, Flinders University, Australia |
|
|
15:10-15:30 |
Coffee Break |
|
|
|
|
Session 1-4: Novel Drug Target Discovery and Validation
|
|
|
|
Dr. Sun-Young Han, Professor, College of Pharmacy, Gyeongsang National University, South Korea |
|
|
Co-Chair |
Call for Co-Chair |
|
|
Speech Time |
Speaker's Profile |
|
|
13:30-13:55 |
Speech Opportunity Available |
|
|
13:55-14:20 |
Speech Opportunity Available |
|
|
14:20-14:45 |
Speech Opportunity Available |
|
|
14:45-15:10 |
Title: TBD
Dr. Dong-Jin Hwang, Research Associate, UTHSC,USA |
|
|
15:10-15:30 |
Coffee Break |
|
|
Day 2, August 13, 2021
AFTERNOON
|
|
Session 1-5: Mass Spectrometry Applications in Drug R&D
|
|
|
|
|
Dr. Kate Comstock, Senior Pharmaceutical Products Manager, Pharma/Biopharma Marketing,
Small Molecule/Extractables & Leachables Analysis, CMD, Thermo Fisher Scientific, USA |
|
|
Co-Chair |
Call for Co-Chair |
|
|
Speech Time |
Speaker's Profile |
|
|
13:30-13:55 |
Speech Opportunity Available |
|
|
13:55-14:20 |
Speech Opportunity Available |
|
|
14:20-14:45 |
Speech Opportunity Available |
|
|
14:45-15:10 |
Dr. Kate Comstock, Senior Pharmaceutical Products Manager, Pharma/Biopharma Marketing,
Small Molecule/Extractables & Leachables Analysis, CMD, Thermo Fisher Scientific, USA |
|
|
15:10-15:30 |
Coffee Break |
|
|
|
|
Session 1-6: Drug Screening Technology
|
|
|
|
Dr. Dong Liang, President&CEO, Aurora Biomed Inc. , Canada |
|
|
Co-Chair |
Call for Co-Chair |
|
|
Speech Time |
Speaker's Profile |
|
|
13:30-13:55 |
Title: Label Free flux Assay for Ion Channel and Transporters – Novel area for Natural Compound and Cancer
Drug Discovery
Dong Liang, President&CEO, Aurora Biomed Inc., Canada |
|
|
13:55-14:20 |
Title: Screening of a protein scaffold library for an inhibitor of IL7 signalling candidate
Frederique Ponchel, Associate Professor, Head of Translational Research in Immune Mediated Inflammatory
Diseases, The University of Leeds, UK |
|
|
14:20-14:45 |
Title: 26 years of DNA-Encoded Chemistry: Managing serendipity in pre-clinical small molecule drug discovery
Dr. Barry Morgan, CSO, HitGen Pharmaceuticals Inc., USA |
|
|
14:45-15:10 |
Speech Opportunity Available |
|
|
15:10-15:30 |
Coffee Break |
|
|
|
|
Session 1-7: Translational Medicine and Drug Discovery
|
|
|
|
Dr. Dr. Hong Ling, CSO&SVP, Leads Biolabs, China |
|
|
Co-Chair |
Dr. Crystal S. Shin, Assistant Professor, Translational Nanomedicine Research Laboratory, Baylor College
of Medicine, USA |
|
|
Speech Time |
Speaker's Profile |
|
|
13:30-13:55 |
Speech Opportunity Available |
|
|
13:55-14:20 |
Title: Translational research through drug discovery and development
Dr. Dr. Hong Ling, CSO&SVP, Leads Biolabs, China |
|
|
14:20-14:45 |
Speech Opportunity Available |
|
|
14:45-15:10 |
Title: TBD
Dr. Crystal S. Shin, Assistant Professor, Translational Nanomedicine Research Laboratory,
Michael E. DeBakey Department of Surgery, Baylor College of Medicine, USA |
|
|
15:10-15:30 |
Coffee Break |
|
|
|
|
Session 1-8: Biomarkers in Drug Discovery & Development
|
|
|
|
|
Dr. Krishna Kumar, Professor of Biopharmaceutics & Pharmacokinetics, Howard University, College of Pharmacy,
USA |
|
|
Co-Chair |
Dr. Hüseyin FIRAT, Professor, CEO-CSO, FIRALIS S.A., France |
|
|
Speech Time |
Speaker's Profile |
|
|
13:30-13:55 |
Speech Opportunity Available |
|
|
13:55-14:20 |
Title: TBD
Dr. Young Juhn, Professor, Director, Precision Population Science Lab; Director, Integrating Special
Population Program of the Mayo Clinic CTSA Program; Department of Pediatrics and Department of
Internal Medicine; Mayo Clinic, USA |
|
|
14:20-14:45 |
Title: TBD
Dr. Hüseyin FIRAT, Professor, CEO-CSO, FIRALIS S.A., France |
|
|
14:45-15:10 |
Speech Opportunity Available |
|
|
15:10-15:30 |
Coffee Break |
|
|
|
|
Session 1-9: Drug Discovery Pharmacology and Toxicology
|
|
|
|
|
Dr. Marco Falasca, Professor, Head Metabolic Signalling Group, School of Pharmacy & Biomedical Sciences,
Faculty of Health Sciences, Curtin University, Australia |
|
|
Co-Chair |
Dr. Vivek (Vic) Kadambi, Senior Vice President, Quantitative Pharmacology & Drug Safety, Blueprint Medicines, USA |
|
|
Speech Time |
Speaker's Profile |
|
|
13:30-13:55 |
Title: Animal Testing Enables Safe Entry to First-In-Human Clinical Trials: The IQ Nonclinical to Clinical
Translational Database
Dr. Vivek (Vic) Kadambi, Senior Vice President, Quantitative Pharmacology & Drug Safety, Blueprint Medicines, USA |
|
|
13:55-14:20 |
Title: Strategic roadmap to increase the antineoplastic activity and to diminish toxicity of anticancer compounds
Dr. Marco Falasca, Professor &Head Metabolic Signalling Group, School of Pharmacy & Biomedical Sciences,
Faculty of Health Sciences, Curtin University, Australia
|
|
|
14:20-14:45 |
Speech Opportunity Available |
|
|
14:45-15:10 |
Title: Repurposing of Clinical Drugs for Radioprotection
Dr. Amit Alok, Scientist D, Division of Radiation Biodosimetry, Institute of Nuclear Medicine & Allied Sciences, India |
|
|
15:10-15:30 |
Coffee Break |
|
|
Day 3, August 14, 2021
MORNING
|
|
Session 1-10: Marine Drugs and Natural Products in Drug Discovery and Development
|
|
|
|
Dr. Lijun NI, Professor, Chemistry & Molecular Engineering School, East China Univ. Sci. & Tech., China |
|
|
Co-Chair |
Call for Co-Chair |
|
|
Speech Time |
Speaker's Profile |
|
|
9:00-9:25 |
Title: A strategy for discovering new candidate Chinese medicine formula based on quantitative pharmacology
analysis
Dr. Lijun NI, Professor, Chemistry & Molecular Engineering School, East China Univ. Sci. & Tech., China |
|
|
9:25-9:50 |
Title: Study of Laccase-Catalysed Synthesis of Urushiol Coumarin Derivatives and as hCA Inhibitor
Dr. Cheng-Zhang Wang, Professor, Institute of Chemical Industry of Forestry Products, China |
|
|
9:50-10:15 |
Title: Study of Laccase-Catalysed Synthesis of Urushiol Coumarin Derivatives and as hCA Inhibitor
Dr. Hao Zhou, Associate professor, Institute of Chemical Industry of Forest Products, CAF, China |
|
|
10:15-10:30 |
Coffee Break |
|
|
10:30-10:55 |
Title: TBD
Dr. Pharkphoom Panichayupakaranant, Assoc. Prof. &Director of Phytomedicine and Pharmaceutical
Biotechnology Excellence Center, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Thailand |
|
|
10:55-11:20 |
Speech Opportunity Available |
|
|
11:20-11:45 |
Title: Establishing a method of analysis and standardization study of oral drops formula from Paronychia argentea extract
Dr. Suleiman Olimat, Professor, Jordan University of Science and Technology, Jordan |
|
|
|
|
Session 1-11: Novel Drug Targets for Personalized Precision Medicine
|
|
|
|
Call for Chair |
|
|
Co-Chair |
Dr. Junwen Wang, Professor of Biomedical Informatics, Center for Individualized Medicine & Department of
Health Sciences Research & Department of Pharmacology and Experimental Therapeutics, Mayo Clinic
Arizona & Affiliate Professor, College of Health Solutions, Arizona State University, USA |
|
|
Speech Time |
Speaker's Profile |
|
|
9:00-9:25 |
Speech Opportunity Available |
|
|
9:25-9:50 |
Speech Opportunity Available |
|
|
9:50-10:15 |
Dr. Junwen Wang, Professor of Biomedical Informatics, Center for Individualized Medicine & Department of
Health Sciences Research & Department of Pharmacology and Experimental Therapeutics, Mayo Clinic
Arizona & Affiliate Professor, College of Health Solutions, Arizona State University, USA |
|
|
10:15-10:30 |
Coffee Break |
|
|
|
|
Session 1-12: Small Molecule Drug Discovery
|
|
|
|
|
Dr. Qun (Max) Dang, Corporate Vice President,CSPC PHARMA LTD., China |
|
|
Co-Chair |
Call for Co-Chair |
|
|
Speech Time |
Speaker's Profile |
|
|
9:00-9:25 |
Speech Opportunity Available |
|
|
9:25-9:50 |
Title: IO therapies beyond checkpoint inhibitors
Dr. Qun (Max) Dang, Corporate Vice President,CSPC PHARMA LTD., China |
|
|
9:50-10:15 |
Speech Opportunity Available |
|
|
10:15-10:30 |
Coffee Break |
|
|
|
|
Session 1-13: CNS Drug Discovery & Therapy
|
|
|
|
|
Dr. Kiminobu Sugaya, Professor of Medicine, Head of Neuroscience, University of Central Florida, USA |
|
|
Co-Chair |
Call for Co-Chair |
|
|
Speech Time |
Speaker's Profile |
|
|
9:00-9:25 |
Title: KS-217, a small molecular compound for neuro- regeneration therapies
Dr. Kiminobu Sugaya, Professor and Head of Neuroscience, Chair of Multidisciplinary Neuroscience Alliance,
College of Medicine, University of Central Florida, Orlando FL, USA |
|
|
9:25-9:50 |
Speech Opportunity Available |
|
|
9:50-10:15 |
Title: Stapled peptide ligands for neuropsychiatric disorders
Dr. Gavin Stewart DAWE, Associate Professor, National University of Singapore, Singapore |
|
|
10:15-10:30 |
Coffee Break |
|
|
Day 3, August 14, 2021
AFTERNOON
|
|
Session 1-14: Cardiovascular Drug Discovery & Therapy
|
|
|
|
|
Dr. John A. Cidlowski, Chief, Signal Transduction Laboratory and Principal Investigator, National Institutes of
Health, USA |
|
|
Co-Chair |
Dr.Moo Hyun Kim, PI, Global Clinical Trial Center
Director, Dept. of Cardiology; Professor, College of Medicine, Dong-A University Hospital, Republic of Korea |
|
|
Speech Time |
Speaker's Profile |
|
|
13:30-13:55 |
Title: New Developments in Corticosteroid Regulation of Heart Disease
John A. Cidlowski, Chief, Signal Transduction Laboratory and Principal Investigator, National Institutes of
Health, USA |
|
|
13:55-14:20 |
Speech Opportunity Available |
|
|
14:20-14:45 |
Speech Opportunity Available |
|
|
14:45-15:10 |
Speech Opportunity Available |
|
|
15:10-15:30 |
Coffee Break |
|
|
|
|
Session 1-15: Anti-Cancer Drug Discovery and Therapy
|
|
|
|
Dr. C. I. Edvard SMITH, Professor, Karolinska Institutet, Sweden |
|
|
Co-Chair |
Dr. Bulent Ozpolat, Associate Professor, Department of Experimental Therapeutics, MD Anderson Cancer Center,
The University of Texas, USA |
|
|
Speech Time |
Speaker's Profile |
|
|
13:30-13:55 |
Title: Development of tumor-targeted RNA nanotherapeutics for breast cancer
Dr. Bulent Ozpolat, Associate Professor, Department of Experimental Therapeutics, MD Anderson Cancer Center,
The University of Texas, USA |
|
|
13:55-14:20 |
Title: Targeted nanoparticles for diagnostic and theranostic applications
Dr. Paul Millner, Professor of Bionanotechnology, Bioincubator Laboratories,Garstang Building, University of Leeds, UK |
|
|
14:20-14:45 |
Title: Future prospects for cancer vaccines
Dr. Nikolai Petrovsky, Professor of Medicine, Flinders University, Austria |
|
|
14:45-15:10 |
Title: Human Papillomavirus Infection in genital Women in four regions of Senegal
Dr. El Hadji Seydou Mbaye, International Agency for Research on Cancer (IARC/WHO), Lyon, France |
|
|
15:10-15:30 |
Coffee Break |
|
|
| 15:30-15:55 |
Speech Opportunity Available |
|
|
| 15:55-16:20 |
Speech Opportunity Available |
|
|
|
|
|
|
Session 1-16: Emerging Infectious Diseases Drug Discovery and Therapy
|
|
|
|
Dr. Jean-Denis Docquier, Associate Professor, Department of Medical Biotechnology, University of Siena, Italy |
|
|
Co-Chair |
Call for Co-Chair |
|
|
Speech Time |
Speaker's Profile |
|
|
13:30-13:55 |
Speech Opportunity Available |
|
|
13:55-14:20 |
Title: Challenges in the discovery and development of new antibiotics addressing resistance in Gram-negative
bacteria
Jean-Denis Docquier, Associate Professor, University of Siena Department of Medical Biotechnology, Italy |
|
|
14:20-14:45 |
Speech Opportunity Available |
|
|
14:45-15:10 |
Title: Nanomaterials for alternative antibacterial therapy
Dr. Hassan Hemeg , Assistant Professor, Department of Clinical Laboratory Sciences, Faculty of Applied
Medical Sciences, Taibah University, KSA |
|
|
15:10-15:30 |
Coffee Break |
|
|
|
|
Session 1-17: Antibody Drug Discovery and Development
|
|
|
|
Dr. Jing Li, Senior Vice President, WuXi Biologics, China |
|
|
Co-Chair |
Dr. Le Sun, CEO, AbMax Biotechnology Co.,Ltd., China |
|
|
Speech Time |
Speaker's Profile |
|
|
13:30-13:55 |
Title: Bispecific antibody discovery and development
Dr. Jing Li, Senior Vice President, WuXi Biologics, China |
|
|
13:55-14:20 |
Title: Removal of ADCC/ADCP functions of IgG1 Fc for safer and more effective antibody drug
Dr. Le Sun, CEO, AbMax Biotechnology Co.,Ltd., China |
|
|
14:20-14:45 |
Dr. Chadwick T. King, Executive Director, Antibody Discovery Research, Site Head Amgen British Columbia, Canada |
|
|
14:45-15:10 |
Title: Structure-based Antigen Design: a rational high-throughput strategy for drug discovery
Dr. ManHee Suh, CTO, Founder, Kactus Biosystems, China |
|
|
15:10-15:30 |
Coffee Break |
|
|
15:30-15:55 |
Title: TBD
Dr. Rui Gong, Professor, Head of Antibody Engineering Group, Center for Emerging Infectious Diseases,
CAS Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Chinese Academy of
Sciences, China |
|
|
15:55-16:20 |
Title: Development of a Bispecific Antibody Targeting VEGF and DLL4 (ABL001/NOV1501/TR009) for Cancer Treatment
Dr. Weon-Kyoo You, Head of R&D, Executive vice President, ABL Bio Inc., Republic of Korea |
|
|
16:20-16:45 |
Speech Opportunity Available |
|
|
|
|
Session 1-18: Biosimilar Drug Product Development
|
|
|
|
Dr. Bert E. Thomas IV, Senior Vice President, Business Development, Bio-Thera Solutions, Ltd., USA |
|
|
Co-Chair |
Call for Co-Chair |
|
|
Speech Time |
Speaker's Profile |
|
|
13:30-13:55 |
Speech Opportunity Available |
|
|
13:55-14:20 |
Title: TBD
Dr. Bert E. Thomas IV, Senior Vice President, Business Development, Bio-Thera Solutions, Ltd., USA |
|
|
14:20-14:45 |
Title: TBD
Dr. Annpey Pong, Merck Research Laboratories, USA |
|
|
14:45-15:10 |
Speech Opportunity Available |
|
|
15:10-15:30 |
Coffee Break |
|
|
|
|
|
|
|
|
|
